^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR6860 (MicroRNA 6860)

    i
    Other names: MIR6860, Hsa-Mir-6860, MIR6860, MicroRNA Mir-6860
    1m
    The KANSL1-ARL17A Fusion Gene Generates Oncogenic chKANSARL and F-circKA RNAs that Synergistically Drive Lung Cancer Progression via a Novel F-circKA/miR-6860/chKANSARL Axis. (PubMed, J Biol Chem)
    Collectively, our study identifies and characterizes a novel F-circKA/miR-6860/chKANSARL regulatory axis, revealing how dual transcriptional outputs from the KANSARL fusion gene can synergistically drive lung cancer progression. These findings highlight a previously unrecognized layer of cooperative regulation between linear and circular fusion RNAs in oncogenesis and provide a new framework for understanding fusion gene-mediated tumorigenesis.
    Journal
    |
    MIR6860 (MicroRNA 6860)
    over2years
    Evaluation of prognostic biomarkers in First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. (EACR 2023)
    The down-regulation of miRNAs that targeted genes involved in interferon signaling seems to be protective in this setting. Validation of identified genes and sncRNAs in an external dataset is ongoing to: confirm our results; generate hypothesis for this standard of care treatment used for PDL1-negative R/M; select cases after immunotherapy failure.
    Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MIR200C (MicroRNA 200c) • MIR1246 (MicroRNA 1246) • MIR335 (MicroRNA 335) • MIR6860 (MicroRNA 6860) • TAP1 (Transporter 1) • TNFSF10 (TNF Superfamily Member 10) • MIR204 (MicroRNA 204) • MIR449A (MicroRNA 449a) • MIR636 (MicroRNA 636)
    |
    PD-L1 negative • miR-200-c expression
    |
    Erbitux (cetuximab)